Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts for Quick CASH $$$ -- Ignore unavailable to you. Want to Upgrade?

To: C Wright who wrote (8204)	6/15/1998 4:12:00 PM
From: John Dwyer	Respond to of 9262

[ARIA] Hey, another biotech I like... I'm going to have to start following this thread more closely!! If Ariad is part of your long-term portfolio, I would keep it. This company is very early stage and has some very impressive science behind it. They have a broad platform technology, from signal transduction to gene therapy to functional genomics. Their regulated gene therapy program is really quite impressive and they should start moving this approach into the clinic within a year. I'm expecting several positive developments over the next year or two and I want to be in ARIA as that unfolds. Good Luck, John